SABCS 2020: Radiation Side-Effects Often Underrecognized in Patients With Breast Cancer
Acute side-effects of radiation therapy (RT) are often underrecognized by the physicians of...
Read More
Meeting Coverage
SABCS 2020: Clinical & Genomic Data Combine for Improved Prognosis & Adjuvant Chemotherapy Guidance
An online tool (RSClin) incorporating clinical-pathologic data and results of the 21-gene...
Read More
SABCS 2020: Improved Outcomes With Neratinib-Based Regimens in CNS Metastases from HER2+ BC
Meeting Brief… A subgroup of patients participating in the randomized phase III NALA study...
Read More
SABCS 2020: Some Older Women With Breast Cancer May Opt to Skip Radiotherapy
The omission of radiotherapy (RT) does not affect overall survival at 10 years after breast...
Read More
SABCS 2020: Pregnancy Less Likely After Breast Cancer Diagnosis
Pregnancy is less likely after prior breast cancer (BC) diagnosis, according to a systematic...
Read More
SABCS: Pregnancy Less Likely After Breast Cancer Diagnosis
MONDAY, Dec. 14, 2020 (HealthDay News) — Pregnancy is less likely after prior breast cancer...
Read MoreASH: Triple Therapy for Multiple Myeloma Reduced Sensory, Pain Scores
Addition of selinexor to bortezomib and dexamethasone reduces neuropathy The triple combination of selinexor, bortezomib, and dexamethasone resulted in less peripheral neuropathy symptoms than the two-drug combination of...
Read MoreASH: Multiple Myeloma Cases to Rise by 13% in Five Years
Projection shows increases by lines of therapy Physicians treating multiple myeloma can expect to see an increase in patients over the next five years, researchers reported at the 2020 virtual meeting of the American Society of...
Read MoreHBM9036 Nasal Spray for Dry Eye Disease
HBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Read MoreAAO 2020: Severe DED in Chronic GVHD: Assessing the Role of Serum Vitamin A
Contributing to this article, Shahzad I. Mian, MD, Professor, Ophthalmology and Visual Sciences, Vice Chair, Clinical Sciences and Learning, Kellogg Eye Center, Michigan Medicine Previous research has shown that patients...
Read MoreACR 2020: Apremilast Sustains PsA Control After 1-Year
Reaching RAPID3 and cDAPSA Treatment Targets Linked with Active PsA Control in DMARD-naïve Patients Treated with Apremilast Disease-modifying anti-rheumatic drug (DMARD)-naïve patients achieving Routine Assessment of Patient...
Read MoreACR 2020: Deucravacitinib Efficacious in Patients With Active PsA
Results from Phase 2 PoS Trial In patients with active psoriatic arthritis (PsA) , deucravacitinib was efficacious versus placebo (PBO) over 16 weeks of treatment. Treatment was well tolerated and the safety profile was...
Read More
FMX 2020: Project Improves Parent-School-Provider Communication
New research was presented at FMX 2020, the 2020 American Academy of Family Physicians virtual...
Read MoreSABCS 2020: CONTESSA, Phase 3 Study of Tesetaxel for Metastatic Breast Cancer
The results of CONTESSA, a Phase 3 study of tesetaxel in the treatment of patients with metastatic breast cancer, have been selected for an oral presentation at the 2020 SABCS, to be held virtually December 8-11, 2020. The...
Read MoreSABCS 2020: Final Invasive Disease-Free Survival Analysis of MonarchE
Homologous recombination deficiency represents a new therapeutic strategy for breast cancer brain metastases Nicola S Cosgrove BACKGROUND: Brain metastatic disease occurs in 10-30% of metastatic breast cancer cases. The...
Read MoreSABCS 2020: Updates on Phase 3 PENELOPE-B
The collaborative Phase 3 PENELOPE-B will be presented at SABCS 2020. No unexpected safety signals were observed. Phase 3 PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival (iDFS) in...
Read MoreSABCS 2020: New Data for HER2 and HER3 Directed DXd ADCs Anticipated
New Data for HER2 and HER3 Directed DXd ADCs at SABCS includes longer follow-up research data for ENHERTU® based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark...
Read MoreWhat to Expect at the 43rd Virtual San Antonio Breast Cancer Symposium 2020
The 43rd Virtual San Antonio Breast Cancer Symposium (SABCS®) will take place from December 8-11, 2020. The SABCS is the premier conference for basic, translational, and clinical cancer research professionals. It is well-known...
Read MoreAmivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC
At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 , lead study investigator Prof. Byoung Chul Cho (Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea) presented the interim...
Read More
AHA 2020: Transgender people have unaddressed heart disease risks
A retrospective study of transgender people using gender-affirming hormone therapy (GAHT) found...
Read More